These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18547991)

  • 21. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma.
    Frangié C; Lefaucheur C; Medioni J; Jacquot C; Hill GS; Nochy D
    Lancet Oncol; 2007 Feb; 8(2):177-8. PubMed ID: 17267332
    [No Abstract]   [Full Text] [Related]  

  • 22. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab in breast cancer: the best is yet to come?
    Puhalla S; Brufsky A
    Oncology (Williston Park); 2009 Apr; 23(4):332, 335. PubMed ID: 19476262
    [No Abstract]   [Full Text] [Related]  

  • 24. Genetic delivery of the murine equivalent of bevacizumab (avastin), an anti-vascular endothelial growth factor monoclonal antibody, to suppress growth of human tumors in immunodeficient mice.
    Watanabe M; Boyer JL; Hackett NR; Qiu J; Crystal RG
    Hum Gene Ther; 2008 Mar; 19(3):300-10. PubMed ID: 18324912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple cutaneous ecchymoses associated with the administration of bevacizumab.
    Trafalis DT; Grivas AA; Athanassiou AE
    J BUON; 2008; 13(4):575-6. PubMed ID: 19145684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bevacizumab therapy for Poems syndrome].
    Doffoel-Hantz V; Jaccard A; Sparsa A; Girault S; Bonnetblanc JM; Bordessoule D; Bédane C
    Ann Dermatol Venereol; 2008 Apr; 135(4):320-1. PubMed ID: 18420085
    [No Abstract]   [Full Text] [Related]  

  • 27. [Surgical session: neovascular glaucoma and anti-vascular endothelial growth factor treatment].
    Laplace O
    J Fr Ophtalmol; 2009 Mar; 32(3):230-5. PubMed ID: 19515340
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation.
    Tatar O; Shinoda K; Kaiserling E; Claes C; Eckardt C; Eckert T; Pertile G; Boeyden V; Scharioth GB; Yoeruek E; Szurman P; Bartz-Schmidt KU; ; Grisanti S
    Br J Ophthalmol; 2009 Feb; 93(2):159-65. PubMed ID: 18838410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The horizon of antiangiogenic therapy for colorectal cancer.
    Olszewski AJ; Grossbard ML; Kozuch PS
    Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete remission of psoriasis following bevacizumab therapy for colon cancer.
    Akman A; Yilmaz E; Mutlu H; Ozdogan M
    Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Third nerve palsy following intravitreal anti-VEGF therapy for bilateral neovascular age-related macular degeneration.
    Micieli JA; Santiago P; Brent MH
    Acta Ophthalmol; 2011 Feb; 89(1):e99-100. PubMed ID: 19925526
    [No Abstract]   [Full Text] [Related]  

  • 32. Expression of the vascular endothelial growth factor (VEGF) gene in epithelial ovarian cancer: an approach to anti-VEGF therapy.
    Hata K; Watanabe Y; Nakai H; Hata T; Hoshiai H
    Anticancer Res; 2011 Feb; 31(2):731-7. PubMed ID: 21378364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
    Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
    J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing outcomes with bevacizumab by better targeting patients and tumors.
    DeMichele A; Fox KR
    Oncology (Williston Park); 2009 Apr; 23(4):339-40. PubMed ID: 19476263
    [No Abstract]   [Full Text] [Related]  

  • 36. Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?
    Mir O; Mouthon L; Alexandre J; Mallion JM; Deray G; Guillevin L; Goldwasser F
    J Natl Cancer Inst; 2007 Jan; 99(1):85-6. PubMed ID: 17202119
    [No Abstract]   [Full Text] [Related]  

  • 37. The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions.
    Wada J; Suzuki H; Fuchino R; Yamasaki A; Nagai S; Yanai K; Koga K; Nakamura M; Tanaka M; Morisaki T; Katano M
    Anticancer Res; 2009 Mar; 29(3):881-8. PubMed ID: 19414323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible skeletal changes after treatment with bevacizumab in a child with cutaneovisceral angiomatosis with thrombocytopenia syndrome.
    Smith AR; Hennessy JM; Kurth MA; Nelson SC
    Pediatr Blood Cancer; 2008 Sep; 51(3):418-20. PubMed ID: 18493993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab local complications.
    Gordon-Angelozzi M; Velez-Montoya R; Fromow-Guerra J; García-Aguirre G; Guerrero-Naranjo JL; Quiroz-Mercado H; Morales-Cantón V
    Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862
    [No Abstract]   [Full Text] [Related]  

  • 40. Biological mechanisms of bevacizumab-associated adverse events.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):999-1007. PubMed ID: 19589038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.